GlobalData on MSN20h
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.
Surge in killer virus in UK with babies admitted to hospital
There has been a surge in cases of a deadly virus with more babies admitted to hospital, according to the UK Health Security ...
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...
Study links social vulnerability and race to lower vaccination rates
Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV ...
Hosted on MSN23h
Real-World Study Confirms RSV Vaccine's Protective Power for Seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...
Lung virus surge fuels fears of 'tripledemic' - with young children at risk
An increase in RSV infections has seen more babies admitted to hospital with severe chest infections, the UK Health Security ...
WebMD21h
RSV Vaccine Shows Strong Protection for Older Adults
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...
The American Journal of Managed Care21h
Upadacitinib May Induce Alopecia Areata in Patients With AD
Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.